The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China

Objective: Due to the initiation of the priority review program in China, many antitumor drugs have been approved for marketing based on phase II clinical trials and short-term surrogate endpoint indicators. This study used approved targeted drugs for the treatment of non-small-cell lung cancer (NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Rui, Mingjun, Wang, Zijing, Fei, Zhengyang, Wu, Yao, Wang, Yingcheng, Sun, Lei, Shang, Ye, Li, Hongchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966682/
https://www.ncbi.nlm.nih.gov/pubmed/35370659
http://dx.doi.org/10.3389/fphar.2022.862640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966682/
https://www.ncbi.nlm.nih.gov/pubmed/35370659
http://dx.doi.org/10.3389/fphar.2022.862640

Ejemplares similares